Ocugen shares swing up on Covid-19 vaccine manufacturing deal

Biopharmaceutical play Ocugen is preparing for potential commercial manufacturing of its Covid-19 vaccine for the US and Canadian markets.

  • Ocugen, Inc (Nasdaq: OCGN) share price rises to US$6.51 per share on Wednesday (16 June 2021)
  • It is working to bring its Covid-19 shot to the US and Canada
  • The company is pursuing full US approval for Covaxin, instead of EUA
  • Ready to trade US stocks? Open an account today

Ocugen stock price: What’s the latest?

Shares of drug developer Ocugen, which plans to bring a Covid-19 vaccine to the US, jumped almost 4% to close at US$6.51 on Wednesday. About 26.3 million shares changed hands.

Year-to-date, the stock price has more than doubled, fuelled by positive news about its Covid-19 vaccine candidate, Covaxin, which Ocugen is co-developing with India-based Bharat Biotech for the US market.

Ocugen recently also secured exclusive rights to co-develop, manufacture and commercialise the vaccine in Canada.

On Wednesday, the biotech announced it was preparing for potential commercial manufacturing of Covaxin in the US and Canada, having selected Jubilant HollisterStier as its manufacturing partner.

Sentiment among research teams turned less bullish over the past month, with three in four analysts rating OCGN shares ‘hold’ and only one recommending ‘buy’.

Their average 12-month target price stood at US$6.13 per share as of Wednesday, Bloomberg data showed, implying a potential downside of 5.8% from the last close. That was also nearly half of the US$12.50 average price target last month.

Why is Ocugen no longer seeking emergency use authorisation?

Despite the string of positive developments, Ocugen’s shares had slumped recently when it said it would file for full US approval of Covaxin, instead of emergency use authorisation (EUA).

OCGN shares sank 28.1% last Thursday (10 June 2021), after the drugmaker’s announcement. The Covid-19 shot is already in use in India.

The decision was made because the US Food and Drug Administration (FDA) had recommended Ocugen take the standard path to a full approval, known as a biologics licence application, which takes many additional months, The New York Times (NYT) reported.

The FDA also requested more information and data for the full approval. Ocugen said it expects data from an additional clinical trial will be required to support the marketing application submission for its Covid-19 vaccine candidate.

‘While this will extend our timelines, we are committed to bringing Covaxin to the US,’ Ocugen added.

NYT noted that this is a sign that the FDA is changing its approach to Covid-19 vaccines in general.

Russell 3000 Index to welcome Ocugen as member

On Wednesday, Ocugen announced that it will join the broad-market Russell 3000 Index after the US stock market opens on 28 June 2021. Membership will be in place for one year.

The annual reconstitution of the Russell indices captures the 4,000 largest US stocks as of 07 May 2021, ranking them by total market capitalisation.

Russell indices are used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

Where do you see the Ocugen share price going?

Take your position on US shares for just a small initial deposit with CFDs.

Whether you trade or invest, you’ll get access to pre-market and after-hours trading on 70 US stocks.

Open an account to get started.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.


Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.